ICU Medical is emerging from a prolonged integration drag, with Q2 2026 gross margin expanding to 42.6% and operating margin tripling sequentially to 7.1%, suggesting cost discipline and mix benefits are taking hold. However, revenue declined 6.4% year-over-ye...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $2.37+24.1% vs $1.91 | $548M+2.7% vs $533M |
Q2 2026 May 7, 2026 | $1.97+10.7% vs $1.78 | $526M+1.0% vs $521M |
Q1 2026 Feb 19, 2026 | $1.91+13.7% vs $1.68 | $536M+1.0% vs $531M |
Q4 2025 Nov 6, 2025 | $2.03+42.0% vs $1.43 | $537M+5.0% vs $511M |
Ambu A/S (OTCMKTS:AMBBY - Get Free Report) and ICU Medical (NASDAQ: ICUI - Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Earnings and Valuation This table compares Ambu
The sale was part of a trading plan established in June.
Jushi (OTCMKTS:JUSHF - Get Free Report) and ICU Medical (NASDAQ: ICUI - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends. Risk and Volatility Jushi has a beta of -0.63,
Bonnell retains 62,443 direct shares.
Benchmark ICUI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ICU Medical, Inc. (ICUI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $163.32 | $4.08B | 5555.10 | -6.38% | 0.03% | 0.04% | — | |
| $182.52 | $50.29B | 31.31 | 8.23% | 4.52% | 3.79% | — | |
| $44.62 | $66.32B | 23.00 | 19.87% | 17.47% | 14.76% | — | |
| $126.32 | $4.29B | 43.71 | 7.57% | 6.97% | 7.43% | — | |
| $35.45 | $2.93B | 14.90 | 1.34% | 11.83% | 8.29% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — |
ICU Medical, Inc. (ICUI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ICU Medical, Inc. (ICUI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 18, 2026·SEC
May 7, 2026·SEC
Get notified when ICUI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ICU Medical, Inc. (ICUI) stock FAQ — growth, dividends, profitability & financials explained
ICU Medical, Inc. (ICUI) reported $2.16B in revenue for fiscal year 2025. This represents a 8678% increase from $24.6M in 1996.
ICU Medical, Inc. (ICUI) saw revenue decline by 6.4% over the past year.
Yes, ICU Medical, Inc. (ICUI) is profitable, generating $30.1M in net income for fiscal year 2025 (0.0% net margin).
ICU Medical, Inc. (ICUI) has a return on equity (ROE) of 0.0%. This is below average, suggesting room for improvement.
ICU Medical, Inc. (ICUI) generated $152.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
